Literature DB >> 28007900

Extensive cryptic splicing upon loss of RBM17 and TDP43 in neurodegeneration models.

Qiumin Tan1,2, Hari Krishna Yalamanchili1,2, Jeehye Park1,2, Antonia De Maio2,3, Hsiang-Chih Lu2,3, Ying-Wooi Wan1,2, Joshua J White2,4,5, Vitaliy V Bondar1,2, Layal S Sayegh1,2, Xiuyun Liu1,2, Yan Gao1,2, Roy V Sillitoe2,3,4,5, Harry T Orr6,7, Zhandong Liu2,8, Huda Y Zoghbi1,2,3,4,5,9.   

Abstract

Splicing regulation is an important step of post-transcriptional gene regulation. It is a highly dynamic process orchestrated by RNA-binding proteins (RBPs). RBP dysfunction and global splicing dysregulation have been implicated in many human diseases, but the in vivo functions of most RBPs and the splicing outcome upon their loss remain largely unexplored. Here we report that constitutive deletion of Rbm17, which encodes an RBP with a putative role in splicing, causes early embryonic lethality in mice and that its loss in Purkinje neurons leads to rapid degeneration. Transcriptome profiling of Rbm17-deficient and control neurons and subsequent splicing analyses using CrypSplice, a new computational method that we developed, revealed that more than half of RBM17-dependent splicing changes are cryptic. Importantly, RBM17 represses cryptic splicing of genes that likely contribute to motor coordination and cell survival. This finding prompted us to re-analyze published datasets from a recent report on TDP-43, an RBP implicated in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), as it was demonstrated that TDP-43 represses cryptic exon splicing to promote cell survival. We uncovered a large number of TDP-43-dependent splicing defects that were not previously discovered, revealing that TDP-43 extensively regulates cryptic splicing. Moreover, we found a significant overlap in genes that undergo both RBM17- and TDP-43-dependent cryptic splicing repression, many of which are associated with survival. We propose that repression of cryptic splicing by RBPs is critical for neuronal health and survival. CrypSplice is available at www.liuzlab.org/CrypSplice.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28007900      PMCID: PMC5968355          DOI: 10.1093/hmg/ddw337

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  51 in total

Review 1.  How prevalent is functional alternative splicing in the human genome?

Authors:  Rotem Sorek; Ron Shamir; Gil Ast
Journal:  Trends Genet       Date:  2004-02       Impact factor: 11.639

2.  TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD.

Authors:  Jonathan P Ling; Olga Pletnikova; Juan C Troncoso; Philip C Wong
Journal:  Science       Date:  2015-08-07       Impact factor: 47.728

Review 3.  Splicing of messenger RNA precursors.

Authors:  R A Padgett; P J Grabowski; M M Konarska; S Seiler; P A Sharp
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

4.  Mitogen-activated protein kinase phosphorylation of splicing factor 45 (SPF45) regulates SPF45 alternative splicing site utilization, proliferation, and cell adhesion.

Authors:  Adnan M Al-Ayoubi; Hui Zheng; Yuying Liu; Tao Bai; Scott T Eblen
Journal:  Mol Cell Biol       Date:  2012-05-21       Impact factor: 4.272

Review 5.  Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.

Authors:  Mario Cazzola; Marianna Rossi; Luca Malcovati
Journal:  Blood       Date:  2012-11-16       Impact factor: 22.113

6.  Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.

Authors:  William L Perry; Robert L Shepard; Janardhan Sampath; Benjamin Yaden; William W Chin; Philip W Iversen; Shengfang Jin; Andrea Lesoon; Kathryn A O'Brien; Victoria L Peek; Mark Rolfe; Andrew Shyjan; Michelle Tighe; Mark Williamson; Venkatesh Krishnan; Robert E Moore; Anne H Dantzig
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

7.  Highly restricted expression of Cre recombinase in cerebellar Purkinje cells.

Authors:  Xin-Mei Zhang; Alam Hoi-Lam Ng; Julian A Tanner; Wu-Tian Wu; Neal G Copeland; Nancy A Jenkins; Jian-Dong Huang
Journal:  Genesis       Date:  2004-09       Impact factor: 2.487

8.  TDP-43 is a developmentally regulated protein essential for early embryonic development.

Authors:  Chantelle F Sephton; Shannon K Good; Stan Atkin; Colleen M Dewey; Paul Mayer; Joachim Herz; Gang Yu
Journal:  J Biol Chem       Date:  2009-12-29       Impact factor: 5.157

9.  RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1.

Authors:  Jeehye Park; Ismael Al-Ramahi; Qiumin Tan; Nissa Mollema; Javier R Diaz-Garcia; Tatiana Gallego-Flores; Hsiang-Chih Lu; Sarita Lagalwar; Lisa Duvick; Hyojin Kang; Yoontae Lee; Paymaan Jafar-Nejad; Layal S Sayegh; Ronald Richman; Xiuyun Liu; Yan Gao; Chad A Shaw; J Simon C Arthur; Harry T Orr; Thomas F Westbrook; Juan Botas; Huda Y Zoghbi
Journal:  Nature       Date:  2013-05-29       Impact factor: 49.962

10.  Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion.

Authors:  Yuying Liu; LaShardai Conaway; Jennifer Rutherford Bethard; Adnan M Al-Ayoubi; Amber Thompson Bradley; Hui Zheng; Scott A Weed; Scott T Eblen
Journal:  Nucleic Acids Res       Date:  2013-03-21       Impact factor: 16.971

View more
  37 in total

1.  Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43.

Authors:  Mingkuan Sun; William Bell; Katherine D LaClair; Jonathan P Ling; Heather Han; Yusuke Kageyama; Olga Pletnikova; Juan C Troncoso; Philip C Wong; Liam L Chen
Journal:  Acta Neuropathol       Date:  2017-03-22       Impact factor: 17.088

2.  The Expanding Toolkit of Translating Ribosome Affinity Purification.

Authors:  Joseph D Dougherty
Journal:  J Neurosci       Date:  2017-12-13       Impact factor: 6.167

3.  Advanced Methods for the Analysis of Altered Pre-mRNA Splicing in Yeast and Disease.

Authors:  Huw B Thomas; Raymond T O'Keefe
Journal:  Methods Mol Biol       Date:  2019

4.  Splicing repression is a major function of TDP-43 in motor neurons.

Authors:  Aneesh Donde; Mingkuan Sun; Jonathan P Ling; Kerstin E Braunstein; Bo Pang; Xinrui Wen; Xueying Cheng; Liam Chen; Philip C Wong
Journal:  Acta Neuropathol       Date:  2019-07-22       Impact factor: 17.088

Review 5.  Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions.

Authors:  Julia K Nussbacher; Ricardos Tabet; Gene W Yeo; Clotilde Lagier-Tourenne
Journal:  Neuron       Date:  2019-04-17       Impact factor: 17.173

Review 6.  TDP43 and RNA instability in amyotrophic lateral sclerosis.

Authors:  Kaitlin Weskamp; Sami J Barmada
Journal:  Brain Res       Date:  2018-01-31       Impact factor: 3.252

7.  Loss of Capicua alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma.

Authors:  Qiumin Tan; Lorenzo Brunetti; Maxime W C Rousseaux; Hsiang-Chih Lu; Ying-Wooi Wan; Jean-Pierre Revelli; Zhandong Liu; Margaret A Goodell; Huda Y Zoghbi
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-30       Impact factor: 11.205

Review 8.  Pathomechanisms of TDP-43 in neurodegeneration.

Authors:  Ju Gao; Luwen Wang; Mikayla L Huntley; George Perry; Xinglong Wang
Journal:  J Neurochem       Date:  2018-02-27       Impact factor: 5.372

Review 9.  Dynamic duo - FMRP and TDP-43: Regulating common targets, causing different diseases.

Authors:  Diana Ferro; Stephen Yao; Daniela C Zarnescu
Journal:  Brain Res       Date:  2018-04-30       Impact factor: 3.252

10.  Trends in Understanding the Pathological Roles of TDP-43 and FUS Proteins.

Authors:  Emanuele Buratti
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.